* Champions Oncology Inc CSBR.OQ CSBR.O is expected to show
a rise in quarterly revenue when it reports results on December
13.
* The Baltimore Maryland-based company is expected to report a
14.2% increase in revenue to $11.549 million from $10.12 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Champions Oncology Inc
is for earnings of 1 cents per share. For the same quarter last
year, the company reported breakeven results per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Champions
Oncology Inc is $16, about 49% above its last closing price
of $8.16.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jul. 31 2021 0.01 0.01 -0.01 Missed -200
Apr. 30 2021 0.00 0.00 -0.04 Missed
Jan. 31 2021 0.00 0.01 0.05 Beat 649.6
Oct. 31 2020 0.00 0.00 0.00 Met
Jul. 0.02 0.02 0.01 Missed -50
31 2020
Apr. 30 2020 0.02 -0.14 Missed -1,033
.3
Jan. 31 2020 0.03 0.03 0.03 Met 12.5
Oct. 31 2019 -0.02 0.01 0.02 Beat 166.7
This summary was machine generated December 10 at 21:11 GMT.
All figures in US dollars unless otherwise stated